Von Hippel-Lindau (VHL) patients and NeuroEndocrine Cancer Australia (NECA) celebrated across Australia this month when the only known treatment for VHL was recommended for listing as part of Australia’s Pharmaceutical Benefits Scheme (PBS).
Until now access to Belzutifan for Australian patients was only available for Australians who are able to live overseas to access this treatment, or, pay AUD $12,000 per month. Through tireless advocacy and working alongside patients and stakeholders, NECA is delighted to share that by Christmas, patients across the country will be able to access Belzutifan for AUD $31.60 per month, or $7.70 if they hold a healthcare card. The community is incredibly relieved and excited for these patients who now face a brighter, more hopeful, healthier future.
